RNU6-659P

Across TCGA pan-cancer cohorts, RNU6-659P RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated RNU6-659P data layer.

The strongest signal is observed in testicular germ cell tumors (TGCT), where higher RNU6-659P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-659P expression acts as an unfavorable survival marker.

TGCT, LUSC, and LUAD are the cancer types where RNU6-659P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
TGCT	OS	Tertile	All	0.508	0.991	<.001	90	view →
LUSC	DFS	Tertile	All	0.315	0.668	<.001	75	view →
LUAD	OS	Tertile	II,III,IV	0.109	0.750	<.001	54	view →
BLCA	DFS	Tertile	All	0.392	0.635	.001	24	view →
UCS	DFS	Tertile	All	0.136	0.523	.034	18	view →
BRCA	DFS	Tertile	II,III,IV	0.245	0.530	.003	12	view →
KIRC	DFS	Tertile	All	0.400	0.657	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RNU6-659P–TGCT (OS)

Open the TGCT breakdown →